Overview
Patients with advanced or progressive endometrial cancer often require multiple lines of treatment; yet, treatment beyond first-line remains heterogeneous and is not defined by a single standard of care. Understanding how these patients are treated in real-world settings can help identify gaps in care and opportunities for improvement.
In this study, researchers analyzed real-world data from nearly 1400 patients receiving second-line or later treatments for advanced endometrial cancer after prior platinum therapy. They found that treatment patterns were highly variable, with decreasing use of platinum-based therapies and increasing reliance on nonplatinum chemotherapy in later lines. Across successive lines of therapy, outcomes worsened, with shorter times to treatment discontinuation, progression, and overall survival.
Why this matters
These findings highlight a significant unmet need for more effective treatments in advanced endometrial cancer. The lack of consistent treatment approaches and declining outcomes with each line of therapy underscore the importance of developing new therapies and optimizing treatment strategies earlier in the disease course.